ViiV Healthcare is to make an upfront payment of $40 million to Halozyme Therapeutics Inc of the US to gain access to a drug delivery technology enabling medicines for HIV to be administered in larger quantities and at longer dosing intervals. The agreement was announced on 22 June by ViiV, which is majority controlled by GlaxoSmithKline Plc. Its new licence will give the company exclusive use of Halozyme’s technology for four specific HIV medicine targets.
